TORONTO, April 19, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced today the filing of a new provisional patent application that…

Source

Previous articleCOMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
Next articleFilament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products